secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARINUS PHARMACEUTICALS, INC. (—)
CIK:        0001267813
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001104659-25-011211
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marinus acquired by Immedica for $0.55/share; merger completed, stock to be delisted
--------------------------------------------------------------------------------

- Tender offer closed Feb 6 with ~67.4% of shares tendered; merger effective Feb 11, 2025.
- Aggregate consideration ~$32.3M; shareholders receive $0.55 cash per share.
- Marinus common stock to cease trading on Nasdaq; company becomes Immedica subsidiary.
- All directors and officers replaced; Anders Edvell named CEO, Simon Falk Treasurer, Nina Fleck Secretary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/tm256024d9_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-011211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer